Share the Video:

What Could the Next Iteration of a Psychedelic State Policy Look Like?

PS2025 Policy

Leonard Gilroy, Barine Majewska, Courtney Barnes, Jared Moffat, Allison Hoots

Oregon and Colorado have pioneered and iterated on the first state-regulated psychedelics markets. But there are many additional ways beyond the Oregon and Colorado models to establish a market. States are the “laboratories of democracy” and this session will explore approaches that state governments could implement in the future, including a retail model or state-regulated production of synthetic psychedelics like MDMA.

Become a MAPS Member with a monthly donation

As a Member, you’re not just making a donation — you’re joining a community that is at the forefront of advancing research, changing policy, and evolving education around psychedelics. Join us in shaping a future where these life-changing tools are available to those who need them most.

Building momentum for new state policy approaches

Expansion of psychedelic policy in the US includes decriminalization, adult use regulations, and increased research funding. Elected state lawmakers discuss challenges, opportunities, and lessons from proposed psychedelic legislation.

Rep La Shawn Ford (IL), Rep Alex Dominguez (TX), Tamar Todd

PS2023 Ancestral Knowledge Indigenous People Plant Medicine Policy Social and Cultural Social Justice

Retelling the story of peyote’s past, present, and future

Address delves into peyote's historical, cultural, and colonial impact, challenging dominant narratives and exploring paths for cultural preservation and religious freedom. Speakers illuminate untold narratives and complexities.

PS2023 Policy Policy and Advocacy Psychedelic Science Public Benefit Research Social Justice

Visionary approaches: psychedelic policy in a global context

International drug policy, historically mirroring US prohibitionist approach, is evolving. Leaders propose regulatory solutions in context of broader drug reform for unified post-prohibition world.

Steve Rolles, Kasia Malinowska

PS2023 Policy Policy and Advocacy Psychedelic Science Research Research and Science Social and Cultural

Psychedelic policy approaches: from the visionary to the pragmatic

Discussion between experts on pragmatic frameworks, demographic considerations, and evidence-based practices shaping psychedelic policy reform for diverse contexts, addressing regulatory challenges and fostering nuanced understanding.

Tatiana Quintana, Melissa Lavasani, Logan Davidson

PS2023 Policy Policy and Advocacy Public Benefit Research Social Justice

Perspectives on the landscape of state and federal reform

Experts and advocates discuss the intricacies of psychedelic policy reform at state and federal levels, highlighting federalism, grassroots movements, expert leverage, and collaborative approaches for equitable drug policies.

Matt C Zorn, Ismail Ali, Brett Waters, Seema Sadanandan, Kathryn L Tucker

PS2023 Policy Policy and Advocacy Psychedelic Science Public Benefit Research Research and Science

Updates from leading statewide regulatory initiatives - Colorado

Oregon’s Psilocybin Services Act and Colorado’s Natural Medicine Health Act are pioneering successful statewide initiatives regulating adult psychedelic substance use. Leaders discuss challenges and lessons learned in implementation.

Rev Veronica Lightning Horse P…, Ean Seeb, Hadas Alterman

PS2023 Policy Policy and Advocacy Psychedelic Science Public Benefit Research Research and Science

Updates from leading statewide regulatory initiatives - Oregon

Oregon’s Psilocybin Services Act and Colorado’s Natural Medicine Health Act are pioneering successful statewide initiatives regulating adult psychedelic substance use, influencing drug policy reforms in eleven other states in 2023.

Angela E Albee, Sam Chapman

PS2023 Business Policy Research and Science

Preparing for inspections of trial sites by the FDA

Commander Gunn, a USPHS officer and FDA Investigator, specializes in international inspections of drug, biologic, and device trial sponsors and study sites. With 13 years of experience, he previously held

Commander Gene Gunn

PS2023 Business Ketamine Policy Research and Science Resources for Therapists

Ketamine Treatment: Current Issues and Controversies

Dr. Bennett explores the expanding field of ketamine treatment, covering current trends, controversies, and potential topics like enantiomers, mail order platforms, provider training, economics, and FDA approval challenges.

What Could the Next Iteration of a Psychedelic State Policy Look Like?

Become a MAPS Member with a monthly donation

Related Videos